Yicura BioMed eyes IPO as CEO says Hong Kong biotech scene needs more patient capital
GlobeAlert Desk · curated from South China Morning Post · East Asia
Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up. Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in an interview. “Biotech start-up fundraising in Hong Kong is never an easy game to play,” Jin said, adding that developing a...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
What the desk knows about this story
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Single-source so far. Treat details as unconfirmed until more publishers report.
Not flagged as developing.
- China canada agree to lift more tariffsKidnappings · China · 6h ago
- Vietnam forestry company director shot at officeShootings · Republic Of · 3m ago
- Long March 12 | SatNet LEO Group TBD?Rocket Launches · CHN · now